Rb Protein’s Dual Role Linked to Breast Cancer Treatment Resistance
A Paradigm Shift in Understanding the Rb Protein
Researchers at the Peter MacCallum Cancer Centre have identified an unexpected biological mechanism involving the retinoblastoma (Rb) protein that drives treatment resistance in hormone receptor-positive breast cancer, according to a study published in the journal Nature.
Hormone receptor-positive (HR+) breast cancer represents the most common subtype of the disease. For years, clinicians have relied on CDK4/6 inhibitors to switch the Rb protein back on, effectively applying natural brakes to slow tumor proliferation. These targeted drugs have transformed clinical outcomes for countless patients, yet resistance remains a persistent barrier in advanced disease management.
Uncovering Hidden Biological Programs
The research team, led by Associate Professor Shom Goel alongside Postdoctoral Research Fellows Dr. April Watt and Dr. Antonio Ahn, utilized molecular analysis to reveal that Rb’s functions are more complex than previously understood. Beyond its canonical role in preventing cells from dividing uncontrollably, Rb can switch specific genes on.
Specifically, the team found that the protein unexpectedly activates a group of genes responding to the hormone oestrogen, imparting resilience to cancer cells and retaining their capacity to resume growth.
“We’ve always viewed Rb as a straightforward tumour suppressor that puts the brakes on cancer cell growth,” Associate Professor Shom Goel said, according to findings released via Scimex. “Our study shows that the story is far more nuanced. While Rb continues to block cell division, it can also switch on biological programs that partially work against its own protective effects.”
The Mechanics of Combination Therapies
This dual functionality helps explain why standard combination regimens—pairing CDK4/6 inhibitors with endocrine therapy—demonstrate high clinical efficacy. According to the research team, the CDK4/6 inhibitor activates Rb to halt cell division, while endocrine therapy suppresses the unwanted oestrogen-driven signals that Rb inadvertently triggers. Together, these therapies allow the tumor-suppressive actions of Rb to dominate.
When Treatment Resistance Takes Hold
However, this delicate balance shifts when cancers acquire resistance to endocrine therapy. In resistant tumors, the oestrogen-related gene program persists regardless of treatment, eroding the clinical utility of CDK4/6 inhibitors. Recognizing this dynamic allows oncologists and translational researchers to rethink how drug resistance develops in clinic settings, pointing toward the need for novel combination therapies that sustain treatment efficacy.
Key Clinical Takeaways and Funding Support
The study outlines core takeaways for the field:
The retinoblastoma (Rb) protein, traditionally categorized strictly as a tumor suppressor that stops cell division, also activates oestrogen-responsive genes that can help cancer cells survive treatment. While CDK4/6 inhibitors successfully switch Rb on to halt tumor growth, endocrine therapy is required to block the separate oestrogen-driven survival signals that Rb concurrently triggers. When tumors become resistant to endocrine therapy, this oestrogen-related gene program continues unchecked, blunting the therapeutic effectiveness of CDK4/6 inhibitors.
Funding for the study published in Nature was provided by Snow Medical, The Mark Foundation, and the Breast Cancer Research Foundation, supporting ongoing efforts to target the less helpful effects of tumor suppressors without compromising their primary protective activity.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.